Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 6/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489585 | 0.91 | BCL2 (0.48) | BCL2MCL1DCTPP1PLA2G2A | |
| SCHEMBL6491012 | 0.90 | BCL2 (0.40) | BCL2MCL1DCTPP1PLA2G2A | |
| SCHEMBL6488244 | 0.88 | LMNA (0.40) | BCL2MCL1DCTPP1KMT2AMAPT | |
| SCHEMBL6501220 | 0.86 | BCL2 (0.40) | BCL2MCL1DCTPP1ADCY10PLA2G2A | |
| SCHEMBL6499570 | 0.86 | BCL2 (0.42) | BCL2MCL1DCTPP1KMT2APLA2G2A | |
| SCHEMBL6498787 | 0.86 | BCL2 (0.40) | BCL2MCL1DCTPP1PLA2G2AMAPT | |
| SCHEMBL6496885 | 0.85 | BCL2 (0.40) | BCL2MCL1DCTPP1MAPT | |
| SCHEMBL6501511 | 0.84 | BCL2 (0.38) | BCL2MCL1DCTPP1MAPT | |
| SCHEMBL6488710 | 0.83 | BCL2 (0.39) | BCL2MCL1DCTPP1PLA2G2AMAPT | |
| SCHEMBL6498621 | 0.82 | AGTR1 (0.40) | BCL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | BCL2 774/4885MCL1 806/4885DCTPP1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.